Integrating functional genomics to accelerate mechanistic personalized medicine

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Deep sequencing technologies have generated vast genetic data, enabling discoveries and genetically guided cancer therapies.
• Despite advances, most cancer genetic events remain untargeted, creating a gap between genetic knowledge and clinical treatment.
• Functional screening methods have advanced for studying drug sensitivity, but clinical applications are limited.

Purpose of the Study:

• To explore the intersection of genomic and functional screening approaches in cancer research.
• To accelerate the understanding of drug sensitivities linked to specific genetic events.
• To elucidate the mechanisms underlying observed drug sensitivity patterns.

Main Methods:

• Utilizing deep sequencing to identify genetic alterations in tumors.
• Employing functional screening assays (ex vivo and in vivo) to assess drug sensitivity.
• Integrating genomic and functional screening data to identify therapeutic strategies.

Main Results:

• Identification of numerous genetic events in cancer that are currently undrugged.
• Demonstration of novel clinical strategies derived from functional screening discoveries.
• Highlighting the potential for combined approaches to improve patient outcomes.

Conclusions:

• The integration of genomic and functional screening is crucial for advancing cancer treatment.
• This combined modality can bridge the biological gap between genetic understanding and clinical application.
• Further research is needed to fully leverage these approaches for personalized cancer therapy.